ORIGINAL RESEARCH
Published on 02 Aug 2022
Phase 1b clinical trial of pucotenlimab (HX008), a novel anti-PD-1 monoclonal antibody, combined with gemcitabine and cisplatin in the first-line treatment of metastatic triple-negative breast cancer
doi 10.3389/fonc.2022.837963
- 1,706 views
- 3 citations